# Junta clínica — PT-pseudo_d49b896a09e6 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_d49b896a09e6",
  "pid": "PT-pseudo_d49b896a09e6",
  "task": 1,
  "psa": 6.7,
  "age": 67,
  "months": 1,
  "pirads": "4",
  "psad": 0.2,
  "psav": 1.78,
  "psap": 4.4,
  "vol": 36.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.7934635,
  "medhx": "Hypercholesterolaemia, Coronary artery disease, Obesity (BMI >30)",
  "meds": "rosuvastatin, aspirin 80 mg, atorvastatin",
  "notes": "PSA 6.7 ng/mL. PI-RADS 4. PSAD 0.20. Prostate volume 36 mL. csPCa 0.79.",
  "pmhx": [
    "Hypercholesterolaemia",
    "Coronary artery disease",
    "Obesity (BMI >30)"
  ],
  "allergies": [],
  "vitals": {
    "weight": "93 kg",
    "height": "178 cm",
    "bmi": "29.4",
    "bp": "146/77 mmHg",
    "hr": "77 bpm",
    "smoking": "Current smoker (17 pack-yr)",
    "last_dental": "3 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "31 Jan 2025",
  "enc_ref": "Dr. P. van Dijk (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "An upward PSA trend alongside a previously positive biopsy necessitates urological review."
    },
    {
      "s": "History",
      "t": "A widowed retired warehouse worker currently residing with his partner presents for surveillance after a positive biopsy yielded a Gleason 6 diagnosis. His medical background includes coronary artery disease, hypercholesterolaemia, and obesity (BMI >30). Daily medication consists of rosuvastatin, atorvastatin, and aspirin 80 mg. He maintains a 17 pack-year smoking history and consumes approximately 19 units of alcohol each week. Despite a consistent running routine covering five kilometres three times weekly, he reports moderate lower urinary tract symptoms scoring 13 on the IPSS scale, absent of significant nocturia or urgency. Cardiology reviewed him in November, confirming stable angina without recent procedures. An unrelated cataract evaluation occurred last month, and he mentions occasional mild fatigue he attributes to seasonal shifts rather than systemic disease. Distance to the hospital exceeds ninety minutes, leading him to prefer telephone consultations when clinically suitable."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: smooth and symmetric; mobility: unremarkable; asymmetry: none. The digital rectal examination confirms a normal prostate without palpable irregularities. General inspection shows a well-nourished individual with a blood pressure reading of 146/77 mmHg and a regular pulse of 77 beats per minute. Palpation of the abdomen reveals a soft, non-tender abdomen free of masses or organomegaly."
    }
  ],
  "occupation": "retired warehouse worker",
  "marital": "Widowed",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Ophthalmology — cataract review"
  ],
  "alcohol": "19 units / week",
  "exercise": "Running 3x/week, 5 km",
  "ipss": "IPSS score: 13/35 (moderate LUTS)",
  "admin": "Lives >90 min from clinic; phone follow-up preferred where clinically safe.",
  "mri_hospital": "UMCG (Groningen)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d49b896a09e6
Task: 1

Encounter: Urology - outpatient on 31 Jan 2025.
Referrer: Dr. P. van Dijk (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 6.7 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.2 ng/mL²
  - PSA velocity: 1.78 ng/mL/yr
  - Prior PSA: 4.4 ng/mL
  - Prostate volume: 36.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7934635 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypercholesterolaemia, Coronary artery disease, Obesity (BMI >30)
  - Problem list / PMHx: Hypercholesterolaemia, Coronary artery disease, Obesity (BMI >30)
  - Current medication: rosuvastatin, aspirin 80 mg, atorvastatin
  - Allergies: NKA
  - Additional notes: PSA 6.7 ng/mL. PI-RADS 4. PSAD 0.20. Prostate volume 36 mL. csPCa 0.79.

Vitals: weight 93 kg, height 178 cm, BMI 29.4, BP 146/77 mmHg, HR 77 bpm. Smoking: Current smoker (17 pack-yr).

Chief complaint: An upward PSA trend alongside a previously positive biopsy necessitates urological review.

History: A widowed retired warehouse worker currently residing with his partner presents for surveillance after a positive biopsy yielded a Gleason 6 diagnosis. His medical background includes coronary artery disease, hypercholesterolaemia, and obesity (BMI >30). Daily medication consists of rosuvastatin, atorvastatin, and aspirin 80 mg. He maintains a 17 pack-year smoking history and consumes approximately 19 units of alcohol each week. Despite a consistent running routine covering five kilometres three times weekly, he reports moderate lower urinary tract symptoms scoring 13 on the IPSS scale, absent of significant nocturia or urgency. Cardiology reviewed him in November, confirming stable angina without recent procedures. An unrelated cataract evaluation occurred last month, and he mentions occasional mild fatigue he attributes to seasonal shifts rather than systemic disease. Distance to the hospital exceeds ninety minutes, leading him to prefer telephone consultations when clinically suitable.

Physical examination: DRE — texture: smooth and symmetric; mobility: unremarkable; asymmetry: none. The digital rectal examination confirms a normal prostate without palpable irregularities. General inspection shows a well-nourished individual with a blood pressure reading of 146/77 mmHg and a regular pulse of 77 beats per minute. Palpation of the abdomen reveals a soft, non-tender abdomen free of masses or organomegaly.

Patient info: retired warehouse worker; Widowed; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 19 units / week; exercise Running 3x/week, 5 km; IPSS score: 13/35 (moderate LUTS).

Recent other appointments: Ophthalmology — cataract review.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.74
  uncertainty  +/- 0.12 epistemic (95% band 0.51-0.98); among patients I cannot tell apart the outcome was 0.82 of 1.00 mixed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 48 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.72: PI-RADS 4, PSA 6.8, PSAD 0.2, age 62, DRE Normal -> DEFER (borderline). He wrote: "All depends if the lesion has grown in size since 2024. If stable no biopsy , if increased in size I will do a biopsy."
  2. distance 0.79: PI-RADS 4, PSA 5.2, PSAD 0.151, age 68, DRE Normal -> BIOPSY (uncertain). He wrote: "Again missing earlier ISUP grading and if the PIRADS 4 lesion is stabile or growing"
  3. distance 0.93: PI-RADS 4, PSA 6.5, PSAD 0.11, age 64, DRE Normal -> DEFER (uncertain). He wrote: "Need initial ISUP grade and MRI in men on active surveillance."

PRECEDENT: DEFER (weighted vote 0.34 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 48 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines suggest that a repeat biopsy is mandated when there is a change in treatment strategy indicated by the MRI. "sion on MRI mandates a repeat biopsy to confirm histological progression before a change in treatment strategy." This requires assessing the MRI findings to determine if a repeat biopsy is necessary.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, I disagree with the suggestion of biopsy because the guideline emphasizes that the MRI findings are decisive for determining the need for a repeat biopsy. EXPERT-COHORT, the finding that the prior positive biopsy means the panel alone does not determine the decision, as the guideline directs attention to the MRI findings to guide the next step.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the documented grade of the prior biopsy: at ISUP 2 or above the guideline sends him to treatment, not to more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA velocity: the guideline suggests that a PSA change alone should not change management based on its weak link with grade progression
laboratory_results - the PSA density: the guideline links PSA density to risk-adapted biopsy guidance via the risk-adapted matrix table.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on the documented Gleason grade from the previous biopsy and the comparison of the current MRI findings against prior studies.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine whether the lesion is compared against an earlier study to guide the need for a repeat biopsy.
  psa_trend (get_psa_trend) -> Assess the PSA velocity to determine if a PSA change alone should change management.
  previous_notes (get_previous_notes) -> Determine the documented grade of the prior biopsy and whether the patient is on a surveillance protocol with a confirmatory biopsy due.
  laboratory_results (get_lab_results) -> Assess the PSA density to guide risk-adapted biopsy guidance via the risk-adapted matrix table.

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade (Gleason/ISUP) of the prior biopsy?
  Q2. Is the lesion on the MRI compared against an earlier study?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
LESION: PI-RADS 4 lesion in the left peripheral zone, mid-gland, measuring approximately 12 x 8 mm.

psa_trend
PSA 3.0 (Oct 2023) rising to 6.7 (Jan 2025), steepest in the last year.

previous_notes
PRIOR GRADE: Gleason 6
BIOPSY SESSIONS: not recorded
SURVEILLANCE: not recorded
TREATMENT: none recorded

laboratory_results
PSA 6.7 ng/mL (24 Dec 2024) rising to 6.7 (24 Dec 2024), shape is a single value.

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes already provided the necessary context regarding the prior biopsy and surveillance status.

WHAT THIS SUPPORTS
FOR sampling this patient now:
PI-RADS 4 lesion in the left peripheral zone, mid-gland, measuring approximately 12 x 8 mm (from radiology_report).
PSA velocity of 1.78 ng/mL/yr (from psa_trend) indicates a significant rise.

AGAINST sampling this patient now:
Prior positive biopsy (from previous_notes) means the tissue diagnosis is already established.

WHERE THIS LEANS
LEAN: defer

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 6.70 ng/mL over 4 points spanning 15 months; velocity +2.95 ng/mL per year; doubling time about 13 months.
PROJECTION at 6 months: 8.9 ng/mL, conformal 95% band 2.6-31.1.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.78
  uncertainty  +/- 0.11 epistemic (95% band 0.56-1.00), of which 0.00 comes from values that had to be imputed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 86% of the time over the 36 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.74  ('firm' tier; weight 3.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.78  ('firm' tier, fusion_full; weight 4.5)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.34  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.76 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('firm' tier, fusion_full). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.
Dissenting on the board: EXPERT-LIBRARY. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents retrieved by the registrar appear to have addressed the moderator's questions, as the `previous_notes` explicitly state "PRIOR GRADE: Gleason 6," and the `radiology_report` indicates "COMPARISON: new."

ALIGNMENT WITH THE PANEL
The panel protocol suggests BIOPSY based on a weighted vote (p=0.76), which is supported by the Expert-FUSION's high probability (p=0.78). However, the panel explicitly notes that the "documented prior grade in the opened documents: none recorded," which is a critical gap.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade (Gleason/ISUP) of the prior biopsy? Answered by the `previous_notes`, which state "PRIOR GRADE: Gleason 6." Q2. Is the lesion on the MRI compared against an earlier study? Answered by the `radiology_report`, which states "COMPARISON: new."

WHAT CARRIES WEIGHT, AND WHY
The documented prior grade (Gleason 6) is highly relevant as the EAU guideline suggests that if the grade is ISUP 2 or above, treatment is indicated, not further tissue sampling. The comparison status (new lesion) is also crucial as per the EAU guideline regarding MRI findings.

MY SUGGESTION TO THE CHAIR
Given the documented Gleason 6 diagnosis from the prior biopsy, the EAU guideline suggests that this indicates a need for treatment rather than further biopsy. Therefore, I suggest deferring the biopsy based on the established prior diagnosis.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

67y male, PSA 6.7, PI-RADS 4, prior biopsy grade not recorded. Rising PSA and new PI-RADS 4 lesion mandate repeat biopsy to determine treatment strategy. No prior biopsy grade recorded, so sampling is required to guide management. Repeat biopsy planned.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
